Advertisement

Determination of cN1A Autoantibodies by Cell-Based Immunofluorescence Cytochemistry

  • Satoshi YamashitaEmail author
  • Nozomu Tawara
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1901)

Abstract

Sporadic inclusion body myositis (sIBM) is a chronic and progressive inflammatory myopathy that is the commonest among population over 50s. Recently, autoantibodies against cytosolic 5′-nucleotidase 1A (cN1A) have been identified in plasma and serum samples from patients with sIBM. So far, various methods have been established to detect the anti-cN1A autoantibodies, which showed a clinical utility of detection of the autoantibodies in the diagnosis of sIBM. Here we describe a novel cell-based assay for detection of the autoantibodies, which seems equivalent in sensitivity and better in specificity for the diagnosis of sIBM, compared with the previous methods.

Key words

Cytosolic 5′-nucleotidase 1A (cN1A) Cell-based assay Sporadic inclusion body myositis Autoantibodies Autoantigens 

Notes

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research (24591269) from the Japan Society for the Promotion of Science (JSPS), Japan; and a Grant-in-Aid for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan. We thank all members of the Department of Diagnostic Medicine and the Department of Neurology, and of Kumamoto University Hospital, for biochemical and histological analyses.

References

  1. 1.
    Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP (1995) Inclusion body myositis and myopathies. Ann Neurol 38(5):705–713.  https://doi.org/10.1002/ana.410380504CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Needham M, Mastaglia FL (2007) Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6(7):620–631.  https://doi.org/10.1016/S1474-4422(07)70171-0CrossRefPubMedGoogle Scholar
  3. 3.
    Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC (2015) Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve 52(4):527–533.  https://doi.org/10.1002/mus.24562CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, Kong SW, Pinkus JL, Amato AA, Elledge SJ, Greenberg SA (2013) Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73(3):408–418.  https://doi.org/10.1002/ana.23840CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, Verbeek MM, Badrising UA, Arnardottir S, Gheorghe K, Lundberg IE, Boelens WC, van Engelen BG, Pruijn GJ (2013) Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 73(3):397–407.  https://doi.org/10.1002/ana.23822CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Salajegheh M, Lam T, Greenberg SA (2011) Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 6(5):e20266.  https://doi.org/10.1371/journal.pone.0020266CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff SK, Pak K, Casciola-Rosen LA, Mammen AL (2016) Cytosolic 5'-Nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken) 68(1):66–71.  https://doi.org/10.1002/acr.22600CrossRefGoogle Scholar
  8. 8.
    Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N, Mozaffar FH, Pestronk A, Mozaffar T (2016) Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry 87(4):373–378.  https://doi.org/10.1136/jnnp-2014-310008CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Greenberg SA (2014) Cytoplasmic 5′-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 50(4):488–492.  https://doi.org/10.1002/mus.24199CrossRefPubMedGoogle Scholar
  10. 10.
    Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, Lamb JA, Cooper RG, Roberts M, Badrising UA, De Bleecker JL, Machado PM, Hanna MG, Plestilova L, Vencovsky J, van Engelen BG, Pruijn GJ (2016) Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 75(4):696–701.  https://doi.org/10.1136/annrheumdis-2014-206691CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tawara N, Yamashita S, Zhang X, Korogi M, Zhang Z, Doki T, Matsuo Y, Nakane S, Maeda Y, Sugie K, Suzuki N, Aoki M, Ando Y (2017) Pathomechanisms of anti-cytosolic 5′-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol 81(4):512–525.  https://doi.org/10.1002/ana.24919CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurology, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations